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Necrolytic migratory erythema is a rare skin condition that consists of migrating areas of erythema with blisters that heal with
hyperpigmentation. It usually occurs in patients with an alpha islet cell tumor of the pancreas—or glucagonoma—and when associated
with glucose intolerance, anemia, hyperglucagonemia, and weight loss defines the glucagonoma syndrome.
We describe a 52-year-old female patient with necrolytic migratory erythema associated with glucagonoma syndrome who had
metastatic disease at presentation and passed away one week after her admission. The autopsy showed a tumor in the body of the
pancreas, which was diagnosed as a neuroendocrine tumor and confirmed by immunohistochemistry.
The diagnosis of necrolytic migratory erythema is a matter of great importance, since it might be an auxiliary tool for the early
detection of glucagonoma.
DESCRIPTORS: Necrolytic migratory erythema. Glucagonoma syndrome. Glucagonoma.
Necrolytic migratory erythema
(NME) is a rare skin condition charac-
teristically presented as an irregular
annular eruption with a serpiginous
advancing border. Bullae may be seen
at the centre of the lesions that subse-
quently erode and become crusted. The
lesions occur most commonly on the
perineum, distal extremities, lower ab-
domen, and face1-4.
NME usually appears as a para-
neoplastic process in patients with al-
pha cell tumor of the pancreas, i.e.,
glucagonoma. Glucagonoma, in asso-
ciation with hyperglucagonemia, glu-
cose intolerance, anemia, and weight
loss, defines the glucagonoma syn-
drome3,4.
Less often, NME may have no cor-
relation with glucagonoma and be re-
lated to celiac disease, malabsorption,
chronic pancreatitis, infection and he-
patic cirrhosis, or extrapancreatic glu-
cagon-secreting tumor ( renal, duode-
nal, or pulmonary)5-12. We describe a
woman with NME associated with
glucagonoma syndrome.
CASE REPORT
A 52-year-old white woman with an
8-month history of pruritic and burning
skin eruption that rapidly progressed to
involve the entire body was referred for
evaluation. The patient presented
marked fatigue, anorexia, weakness,
confusion, and a 20-pound weight loss
over the previous 8 months.
She was treated with topical and
systemic steroids (prednisone 20 mg/
day) for 2 months without clinical im-
provement. There was no history of al-
cohol intake or diabetes mellitus.
Examination revealed a cachectic
woman with symmetrical erythema-
tous, scaling and crusted annular
plaques that were particularly promi-
nent around perineum (Fig. 1). The le-
sions appeared as urticarial papules and
small vesicles on the trunk. Symmet-
ric erythema, blisters, and edema were
observed on the legs and feet. Super-
ficial erosions were present in the in-
tertriginous areas. Glossitis and angu-
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lar stomatitis were also noted. The
clinical differential diagnosis included
zinc deficiency, pellagra, pemphigus
vulgaris, and NME.
Examination of biopsy specimens
showed an intraepidermal cleft, pres-
ence of vacuolated pale epidermal cells
with pyknotic nuclei, and neutrophils
in the upper epidermis (Fig. 2)—all
changes consistent with NME.
A computed tomography scan of
the abdomen revealed a 3-cm pancre-
atic mass (Fig. 3) and multiple meta-
static nodules in both lobes of the liver.
The serum glucagon level was
markedly increased to 4517.1 pg/mL
(normal 50 to 150 pg/mL). Glycemia
was increased to 204 mg/100 mL (nor-
mal 70 to 100 mg/mL), hematocrit
value was 22.1 (normal 35-45), and all
serum amino acid levels were de-
creased. The serum zinc level was
within normal limits. With the support
of these findings, the diagnosis of
NME associated with glucagonoma
syndrome was made.
The patient developed acute respi-
ratory distress syndrome and died of
acute respiratory failure a week after
the admission. No specific treatment
was performed.
The autopsy showed 4 pale, hard
masses in the body of the pancreas and
multiple pale metastatic nodules in
both lobules of the liver ranging from
0.5 to 5.0 cm. On microscopic exami-
nation, the tumor was composed of
small, relatively uniform cuboidal cells
with centrally located nuclei and finely
granular acidophilic cytoplasm, result-
ing in defined nests, separated by
highly vascularized stroma (solid pat-
tern) (Fig. 4). There was no evidence
of glandular or trabecular differentia-
tion. Mitotic figures were scarce. Im-
munohistochemical staining for
chromogranin was strongly positive,
while synaptophysin, insulin, gluca-
gon, and somatostatin were negative.
DISCUSSION
Becker et al.13 described in 1942 a
“diffuse progressive epidermal necrotic
rash” associated with pancreatic neo-
plasm. In 1966, McGravan et al.14 re-
ported hyperglucagonemia in a patient
with an eczematoid, erythematous rash,
mild diabetes mellitus, anemia, and a
glucagon-secreting alpha cell tumor of
the pancreas.
Mallinson et al.2 in 1974 defined
the glucagonoma syndrome as pre-
sented in 9 patients with diabetes
mellitus, anemia, weight loss, a distinc-
tive rash referred as “necrolytic migra-
tory erythema” (NME), and tumor of
the islet cells of the pancreas. Glossi-
tis, stomatitis, cheilitis, diffuse alo-
pecia, diarrhea, hypoaminoacidemia,
increased incidence of thromboembo-
lism, and psychiatric disturbances com-
plete the glucagonoma syndrome15.
Our patient had this rare and com-
Fig. 1 - Scaling annular lesions around perineum.
Fig. 2 - Biopsy specimen shows an intraepidermal cleft, vacuolated pale keratinocytes with pyknotic
nuclei and neutrophils (HE 400X).

REV. HOSP. CLÍN. FAC. MED. S. PAULO 56(6):183-188, 2001NOVEMBER-DECEMBER
plete syndrome, with metastatic disease
at presentation, similar to what is re-
ported in literature16.
Immunocytochemical findings
show that glucagonoma has two dis-
tinct types: One associated with the
glucagonoma syndrome, presented as
a solitary and large tumor, with a solid
microscopic pattern, low or lack of im-
munoreactivity for glucagon and high
incidence of malignancy (60% of pa-
tients); the other one, not associated
with glucagonoma syndrome, has
tumors that are often multiple and
small, have a gyriform microscopic
pattern of growth, are strongly immu-
noreactive for glucagon, and are al-
ways benign17-20 .
The macroscopic and microscopic
patterns of our patient’s tumor were
those of a neuroendocrine neoplasm of
pancreatic islet cells. The positive im-
munohistochemistry for chromogranin
confirmed this diagnosis. The negative
immunohistochemistry for glucagon
does not exclude the possibility of
glucagonoma, since the majority of
glucagonoma cases associated with this
syndrome present low levels or lack
immunohistochemical reactivity to glu-
cagon.
There are many theories about the
pathogenesis of NME. The effects on
the skin of the glucagonoma syndrome
that result in NME may be due directly
to glucagon itself or to other factors.
The increased level of glucagon as
a direct cause of NME is supported by
some evidence: the demonstration in
vitro that an increased level of gluca-
gon yields greater amounts of epider-
mal arachidonic acid, which causes the
inflammatory changes in the skin21; the
cure of NME after surgical removal of
the tumor, with consequent normaliza-
tion of serum glucagon levels22-25; and
the remission of the rash after therapy
with somatostatin analogue (octreo-
tide), which is a potent inhibitor of glu-
cagon release26,27.
However, other evidence fails to
link NME with hyperglucagonemia,
e.g., the report that only 52% of pa-
tients with non-glucagonoma-associ-
ated NME had an increased glucagon
level12.
Other theories that could explain
the genesis of NME are based on the
secondary effects of glucagon. Gluca-
gon stimulates glycogenolysis, gluco-
neogenesis, ketogenesis, and conse-
quently a systemic catabolic state28.
The hypoaminoacidemia secondary to
increased gluconeogenesis is suggested
by some reports as a cause of NME29,30.
However, several patients cleared the
cutaneous lesions after amino acid in-
fusions29, and some patients with
necrolytic migratory erythema had a
normal amino acid level7,31, or did not
improve after the supplementation22.
Delaney and Uff 32 controlled NME
using omega-3 triglycerides in a patient
with a surgically unresectable gluca-
gonoma. Also, improvement of the
Fig. 3 - Pancreatic mass and metastatic nodules in the liver in computed tomography scan.
Fig. 4 - Pancreatic neuroendocrine neoplasm with a solid microscopic pattern (HE 100X).
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rash has been observed after zinc sup-
plementation in patients who have
a low 8,33 or normal serum zinc level9,34.
The clinical and histologic similari-
ties between NME, hereditary acroder-
matitis, enteropathica secondary to zinc
deficiency, pellagra, and fatty acid de-
ficiency have been noted35-36. The re-
semblance may be explained by this
catabolic state.
Unfortunately, in the present case,
the diagnosis was confirmed at a late
stage of the disease, and the ideal treat-
ment was not instituted. This case il-
lustrates the importance of early recog-
nition of NME, with its distinctive
clinical and histopathologic features, as
well as signs and symptoms that com-
pose the glucagonoma syndrome.
These data suggest that the cause
for the NME associated with gluca-
gonoma is multifactorial, and it is
likely that the postulated theories are
not mutually exclusive.
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O eritema necrolítico migratório é
uma rara condição cutânea que se apre-
senta como lesões eritematosas, migra-
tórias, com vesículas e bolhas na super-
fície, evoluindo para cura com hiper-
pigmentação. É freqüentemente obser-
vado em doentes com tumor de célu-
las alfa do pâncreas, ou glucagonoma,
e quando associado com intolerância a
glicose, anemia, hiperglucagonemia, e
perda de peso definem a síndrome do
glucagonoma.
É descrito o caso de uma paciente
do sexo feminino, 52 anos, branca,
com eritema necrolítico migratório as-
sociado à síndrome do glucagonoma
com doença metastática na apresenta-
ção, vindo a falecer uma semana após
sua admissão. A autópsia mostrou um
tumor no corpo do pâncreas diagnos-
ticado como tumor neuroendócrino e
confirmado pela imuno-histoquímica.
O reconhecimento do eritema necro-
lítico migratório é de grande importân-
cia para a possibilidade de diagnóstico
precoce do glucagonoma.
DESCRITORES: Eritema necro-
lítico migratório. Síndrome gluca-
gonoma. Glucagonoma.
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